Bausch + Lomb Corporation

NYSE:BLCO Stock Report

Market Cap: US$5.4b

Bausch + Lomb Future Growth

Future criteria checks 3/6

Bausch + Lomb is forecast to grow earnings and revenue by 61.8% and 5.5% per annum respectively. EPS is expected to grow by 65% per annum. Return on equity is forecast to be 7.1% in 3 years.

Key information

61.8%

Earnings growth rate

65.02%

EPS growth rate

Medical Equipment earnings growth16.1%
Revenue growth rate5.5%
Future return on equity7.13%
Analyst coverage

Good

Last updated02 Jun 2026

Recent future growth updates

Recent updates

Seeking Alpha • May 26

Bausch + Lomb: Even Though Growth Continues, I Don't See A Way Higher

Summary Bausch + Lomb delivers strong revenue growth and improving profitability, but the share price remains in fair value territory, warranting a 'Hold' rating. BLCO's Vision Care segment, driven by Lumify and SiHy Daily lenses, is a key growth engine with new product launches planned through 2029. Pharmaceuticals and Surgical segments show robust sales and profit gains, supported by innovative products like MIEBO, XIIDRA, and enVista Envy. Management raised 2026 revenue guidance to $5.42–$5.52 billion and EBITDA to $1.01–$1.06 billion, but valuation is not compelling versus peers. Read the full article on Seeking Alpha
Narrative Update • Apr 17

$BLCO $BHC $COO file their ARS annual financial reports and Proxy statements stating divestiture of Lens Care Vision units but no announcem

Who benefits when $BLCO $COO $BHC do not make announcements about Vision business units are divested? Not shareholders… in my opinion
Narrative Update • Apr 14

$BLCO $BHC $COO BHC’s ARS clearly states the divestment and discontinuation of the Vision Care Business! When will the finally announce!

$BHC divestment of $BLCO stated in the ARS financials
Narrative Update • Apr 11

$Cooper $Bausch + Lomb Corporation  DEAL‑CERTAINTY SCORECARD (Final, Fully Integrated Version from AI and my opinion Score: 100/100 — Maxi

$BLCO & $COO Pre-Merger Research Opinion
New Narrative • Apr 07

$BLCO & $COO The Silence BEFORE the AGM: A Retail Investor’s Timeline, Findings, and Opinion on SUSPICIOUS SILENCE!

$BLCO & $COO. The Silence After the AGM: A Retail Investor’s Timeline, Findings, and Opinion on an Unprecedented Governance Failure By a Retail Investor and Portfolio Manager (Opinion) --- I.
Seeking Alpha • Feb 21

Bausch + Lomb: Solid 2024 Results, But Let's Address The Elephant In The Room

Summary Bausch + Lomb reported solid Q4 and full-year 2024 earnings, with CEO Brent Saunders highlighting positives while avoiding the critical issue of Bausch Health's potential sale of its 88% stake. The company's performance review for 2024 was strong, but the future share price trajectory hinges on whether Bausch Health will divest its majority ownership. Investors are closely watching Bausch Health's decision, as it remains the key factor influencing Bausch + Lomb's market valuation and investor sentiment. Read the full article on Seeking Alpha
Seeking Alpha • Dec 07

Bausch + Lomb And Bausch Health: Some Incremental Progress As We Wait For Sale News

Summary Bausch Health Companies Inc.'s debt burden remains a critical issue, with over $21 billion in long-term debt, making a sale of Bausch + Lomb Corporation a potential solution. Bausch + Lomb's Q3 performance showed revenue growth and a shift to net income, driven by new products like Xiidra and Miebo. Despite bankruptcy rumors, major institutional investors like Carl Icahn and Paulson & Co. suggest strategic moves could prevent such an outcome. Both Bausch Health and Bausch + Lomb retain “Buy” ratings due to potential debt resolution strategies and promising growth metrics, respectively. Read the full article on Seeking Alpha
Seeking Alpha • Sep 19

With Buyout Interest, Bausch + Lomb May Still Be Worth Interest At Current Levels

Summary Bausch + Lomb stock has rebounded since January, but still offers value, especially with potential takeover interest and a solid balance sheet. BLCO shares trade at a reasonable premium to forward earnings, with a current ratio of 1.66, providing flexibility despite recent unprofitability. Risks include potential failure of takeover, economic downturns, inflation, and majority ownership by BHC, which could affect independent operations. I rate Bausch + Lomb stock a buy, given its decent deal relative to book value and potential for market recognition or acquisition premium. Read the full article on Seeking Alpha
Seeking Alpha • May 24

Bausch + Lomb's Bet-The-Farm Xiidra Acquisition Is Looking Questionable, But Miebo Could Make The Stock A Winner

Summary Bausch + Lomb (BLCO) is a company with entrenched brands but poor recent financial performance. The company issued debt to acquire Dry Eye Disease [DED] drug Xiidra, hoping to ramp revenue to a more sensible level given their high fixed costs. The acquisition is not going well. Despite deploying substantial marketing expenses, Xiidra's revenue is mediocre and declining. However, BLCO also owns DED drug Miebo, a drug with tremendous potential. Read the full article on Seeking Alpha
Seeking Alpha • Jan 31

Hovering Around 52-Week Low, Bausch + Lomb May Be Poised For A Rebound

Summary Bausch + Lomb is a top company in the global eye health care industry, with over 400 products and operations in over 100 countries. The company is focused on its core business of vision care, ophthalmic pharmaceuticals, and surgical equipment. Despite being near a 52-week low, Bausch + Lomb is financially stable with a high current ratio and expected growth in revenue and earnings. Read the full article on Seeking Alpha

Earnings and Revenue Growth Forecasts

NYSE:BLCO - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20286,09828754984110
12/31/20275,77914339166113
12/31/20265,467-5523273813
3/31/20265,208-2191340N/A
12/31/20255,101-360-66283N/A
9/30/20254,976-305-196169N/A
6/30/20254,891-273-165186N/A
3/31/20254,829-362-168166N/A
12/31/20244,791-317-59232N/A
9/30/20244,684-368-58225N/A
6/30/20244,495-456-137119N/A
3/31/20244,314-337-13180N/A
12/31/20234,146-260-198-17N/A
9/30/20233,969-207-20127N/A
6/30/20233,904-141-57106N/A
3/31/20233,810-104116286N/A
12/31/20223,7686170345N/A
9/30/20223,77358144348N/A
6/30/20223,780136398594N/A
3/31/20223,773175482688N/A
12/31/20213,765182680873N/A
9/30/20213,708-78636845N/A
6/30/20213,675-53539776N/A
3/31/20213,517-44370618N/A
12/31/20203,412-18263522N/A
12/31/20193,778298N/A799N/A
12/31/20183,665710N/A763N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BLCO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.5%).

Earnings vs Market: BLCO is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BLCO is expected to become profitable in the next 3 years.

Revenue vs Market: BLCO's revenue (5.5% per year) is forecast to grow slower than the US market (11.8% per year).

High Growth Revenue: BLCO's revenue (5.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BLCO's Return on Equity is forecast to be low in 3 years time (7.1%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/09 11:35
End of Day Share Price 2026/06/09 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bausch + Lomb Corporation is covered by 18 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew MiksicBarclays
Travis SteedBofA Global Research
Joanne WuenschCitigroup Inc